Review

gad67 (Boster Bio)

Boster Bio is a verified supplier

Boster Bio manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Boster Bio gad67

Effect of GnRH on the E/I balance of ACC neurons induced by CFA injection . ( A ) The localization of GnRHR (red) with CamKII (green) and <t>GAD67</t> (green) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin protein, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 per group for western blot. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; CaMKII, calcium/calmodulin-dependent protein kinase II; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2.

Gad67, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gad67/product/Boster Bio
Average 94 stars, based on 1 article reviews

gad67 - by Bioz Stars, 2026-05

94/100 stars

Images

1) Product Images from "Gonadotropin-releasing hormone alleviates chronic pain-related depression in male mice by rebalancing the anterior cingulate cortex excitatory-inhibitory processes via the protein kinase C/Erb-B2 receptor tyrosine kinase 4 pathway"

Article Title: Gonadotropin-releasing hormone alleviates chronic pain-related depression in male mice by rebalancing the anterior cingulate cortex excitatory-inhibitory processes via the protein kinase C/Erb-B2 receptor tyrosine kinase 4 pathway

Journal: Brain Communications

doi: 10.1093/braincomms/fcag138

Effect of GnRH on the E/I balance of ACC neurons induced by CFA injection . ( A ) The localization of GnRHR (red) with CamKII (green) and GAD67 (green) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin protein, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 per group for western blot. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; CaMKII, calcium/calmodulin-dependent protein kinase II; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2.

Figure Legend Snippet: Effect of GnRH on the E/I balance of ACC neurons induced by CFA injection . ( A ) The localization of GnRHR (red) with CamKII (green) and GAD67 (green) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin protein, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 per group for western blot. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; CaMKII, calcium/calmodulin-dependent protein kinase II; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2.

Techniques Used: Injection, Western Blot, Over Expression, Saline, Adjuvant

ErbB4 is the downstream target of GnRH signalling to regulate the E/I balance and pain-related depression-like behaviour induced by CFA injection . ( A ) The localization of GnRHR (green) with ErbB4 (red) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein level of p-ErbB4 are demonstrated by western blot and the semiquantitative analysis of p-ErbB4 relative to ErbB4, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of p-ErbB4 are demonstrated by western blot and the semiquantitative analysis of p-ErbB4 relative to ErbB4, and the original uncropped blots are shown in . ( D ) The experimental timeline for Trip and dacomitinib treatment after CFA injection. ( E ) Effects of Trip and dacomitinib treatment on the total movement distance of mice in the OFT. ( F ) Effects of Trip and dacomitinib treatment on the sucrose preference rate of 1% sucrose solution in the SCPT. ( G ) Effects of Trip and dacomitinib treatment on the immobility time within 4 min in the TST. ( H ) Effects of Trip and dacomitinib treatment on the immobility time within 4 min in the FST. ( I ) Effects of Trip and dacomitinib treatment on the protein levels of p-ErbB4, GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to ErbB4 or β-actin, and the original uncropped blots are shown in . n = 6 mice per group for western blot test and n = 4–5 per group for behaviour tests and any value >2 SD from the group mean was considered an outlier and excluded from the analysis. One-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among Trip or dacomitinib treatment groups. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among Lv-GnRH overexpression groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; ErbB4, Erb-B2 receptor tyrosine kinase 4; p-ErbB4, phosphorylated-Erb-B2 receptor tyrosine kinase 4; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; Dac, dacomitinib; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2; OFT, open field test; SCPT, sucrose preference test; TST, tail suspension test; FST, forced swimming test.

Figure Legend Snippet: ErbB4 is the downstream target of GnRH signalling to regulate the E/I balance and pain-related depression-like behaviour induced by CFA injection . ( A ) The localization of GnRHR (green) with ErbB4 (red) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein level of p-ErbB4 are demonstrated by western blot and the semiquantitative analysis of p-ErbB4 relative to ErbB4, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of p-ErbB4 are demonstrated by western blot and the semiquantitative analysis of p-ErbB4 relative to ErbB4, and the original uncropped blots are shown in . ( D ) The experimental timeline for Trip and dacomitinib treatment after CFA injection. ( E ) Effects of Trip and dacomitinib treatment on the total movement distance of mice in the OFT. ( F ) Effects of Trip and dacomitinib treatment on the sucrose preference rate of 1% sucrose solution in the SCPT. ( G ) Effects of Trip and dacomitinib treatment on the immobility time within 4 min in the TST. ( H ) Effects of Trip and dacomitinib treatment on the immobility time within 4 min in the FST. ( I ) Effects of Trip and dacomitinib treatment on the protein levels of p-ErbB4, GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to ErbB4 or β-actin, and the original uncropped blots are shown in . n = 6 mice per group for western blot test and n = 4–5 per group for behaviour tests and any value >2 SD from the group mean was considered an outlier and excluded from the analysis. One-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among Trip or dacomitinib treatment groups. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among Lv-GnRH overexpression groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; ErbB4, Erb-B2 receptor tyrosine kinase 4; p-ErbB4, phosphorylated-Erb-B2 receptor tyrosine kinase 4; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; Dac, dacomitinib; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2; OFT, open field test; SCPT, sucrose preference test; TST, tail suspension test; FST, forced swimming test.

Techniques Used: Injection, Western Blot, Over Expression, Saline, Adjuvant, Suspension

GnRH activates ErbB4 via the PKC pathway in the ACC of mice after CFA injection . ( A ) Effects of Trip treatment on the protein levels of PKCα and p-MARCKS are demonstrated by western blot and the semiquantitative analysis of PKCα and p-MARCKS relative to β-actin and MARCKS, and the original uncropped blots are shown in . ( B ) The experimental timeline for Trip and bisindolylmaleimide I treatment after CFA injection. ( C ) Effects of Trip and bisindolylmaleimide I treatment on the total movement distance by mice in the OFT. ( D ) Effects of Trip and bisindolylmaleimide I treatment on the sucrose preference rate of 1% sucrose solution in the SCPT. ( E ) Effects of Trip and bisindolylmaleimide I treatment on the immobility time within 4 min in the TST. ( F ) Effects of Trip and bisindolylmaleimide I treatment on the immobility time within 4 min in the FST. ( G ) Effects of Trip and bisindolylmaleimide I treatment on the protein levels of PKCα, p-MARCKS and p-ErbB4 were demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, MARCKS and ErbB4, and the original uncropped blots are shown in . ( H ) Effects of Trip and bisindolylmaleimide I treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 mice for western blot test and n = 6–9 mice per group for behaviour tests and any value >2 SD from the group mean was considered an outlier and excluded from the analysis. One-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; ErbB4, Erb-B2 receptor tyrosine kinase 4; p-ErbB4, phosphorylated-Erb-B2 receptor tyrosine kinase 4; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; PKCα, protein kinase C α; MARCKS, myristoylated alanine-rich C kinase substrate; p-MARCKS, phosphorylated-myristoylated alanine-rich C kinase substrate; Trip, triptorelin; Bis I, bisindolylmaleimide I; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2; OFT, open field test; SCPT, sucrose preference test; TST, tail suspension test; FST, forced swimming test.

Figure Legend Snippet: GnRH activates ErbB4 via the PKC pathway in the ACC of mice after CFA injection . ( A ) Effects of Trip treatment on the protein levels of PKCα and p-MARCKS are demonstrated by western blot and the semiquantitative analysis of PKCα and p-MARCKS relative to β-actin and MARCKS, and the original uncropped blots are shown in . ( B ) The experimental timeline for Trip and bisindolylmaleimide I treatment after CFA injection. ( C ) Effects of Trip and bisindolylmaleimide I treatment on the total movement distance by mice in the OFT. ( D ) Effects of Trip and bisindolylmaleimide I treatment on the sucrose preference rate of 1% sucrose solution in the SCPT. ( E ) Effects of Trip and bisindolylmaleimide I treatment on the immobility time within 4 min in the TST. ( F ) Effects of Trip and bisindolylmaleimide I treatment on the immobility time within 4 min in the FST. ( G ) Effects of Trip and bisindolylmaleimide I treatment on the protein levels of PKCα, p-MARCKS and p-ErbB4 were demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, MARCKS and ErbB4, and the original uncropped blots are shown in . ( H ) Effects of Trip and bisindolylmaleimide I treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 mice for western blot test and n = 6–9 mice per group for behaviour tests and any value >2 SD from the group mean was considered an outlier and excluded from the analysis. One-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; ErbB4, Erb-B2 receptor tyrosine kinase 4; p-ErbB4, phosphorylated-Erb-B2 receptor tyrosine kinase 4; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; PKCα, protein kinase C α; MARCKS, myristoylated alanine-rich C kinase substrate; p-MARCKS, phosphorylated-myristoylated alanine-rich C kinase substrate; Trip, triptorelin; Bis I, bisindolylmaleimide I; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2; OFT, open field test; SCPT, sucrose preference test; TST, tail suspension test; FST, forced swimming test.

Techniques Used: Injection, Western Blot, Saline, Adjuvant, Suspension

Image Search Results

( A ) Representative traces of mEPSC in primary hippocampal neuron infected with control (empty vector), DOC2A Full-Length , or DOC2A ∆Val217-Pro218 AAV. ( B and C ) Quantification of mEPSC amplitude and frequency. N ≥ 29 neurons. ( D ) Representative traces of mIPSC in in primary hippocampal neuron infected with control, DOC2A Full-Length , or DOC2A ∆Val217-Pro218 AAV. ( E and F ) Quantification of mIPSC amplitude and frequency. N ≥ 20 neurons. ( G ) Representative gels of Western blot. ( H to K ) Quantification of synaptophysin, VAMP-2, GAD65, and GAD67 expression in hippocampus tissue overexpressing control, DOC2A Full-Length , or DOC2A ∆Val217-Pro218 . N = 3 in each group. Full Western blotting images are shown in fig. S16. Data are presented as the means ± SEM; * P < 0.05, ** P < 0.01, and *** P < 0.001. Error bars indicate the SEM.

Journal: Science Advances

Article Title: A causal coding variant regulating alternative splicing of DOC2A at 16p.11.2 GWAS locus influences susceptibility to schizophrenia

doi: 10.1126/sciadv.adw7667

Figure Lengend Snippet: ( A ) Representative traces of mEPSC in primary hippocampal neuron infected with control (empty vector), DOC2A Full-Length , or DOC2A ∆Val217-Pro218 AAV. ( B and C ) Quantification of mEPSC amplitude and frequency. N ≥ 29 neurons. ( D ) Representative traces of mIPSC in in primary hippocampal neuron infected with control, DOC2A Full-Length , or DOC2A ∆Val217-Pro218 AAV. ( E and F ) Quantification of mIPSC amplitude and frequency. N ≥ 20 neurons. ( G ) Representative gels of Western blot. ( H to K ) Quantification of synaptophysin, VAMP-2, GAD65, and GAD67 expression in hippocampus tissue overexpressing control, DOC2A Full-Length , or DOC2A ∆Val217-Pro218 . N = 3 in each group. Full Western blotting images are shown in fig. S16. Data are presented as the means ± SEM; * P < 0.05, ** P < 0.01, and *** P < 0.001. Error bars indicate the SEM.

Article Snippet: The primary antibodies were as follows: FLAG (Cell Signaling Technology, no. 8146S; 1:1000) and DOC2A (Invitrogen, no. PA5-31345; 1:1000), GAD67 (Proteintech, no. 10408-1-AP; 1:5000), GAD65 (Cell Signaling Technology, no. 5843T; 1:1000), synaptophysin (Sigma-Aldrich, no. S5768; 1:500), VAMP-2 (Synaptic Systems, no. 104211; 1:2000), α-tubulin (Proteintech, no. 66031-1-Ig; 1:20,000), and GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Proteintech, no. 10494-1-AP; 1:20,000).

Techniques: Infection, Control, Plasmid Preparation, Western Blot, Expressing

Journal: Brain Communications

doi: 10.1093/braincomms/fcag138

Figure Lengend Snippet: Effect of GnRH on the E/I balance of ACC neurons induced by CFA injection . ( A ) The localization of GnRHR (red) with CamKII (green) and GAD67 (green) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin protein, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 per group for western blot. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; CaMKII, calcium/calmodulin-dependent protein kinase II; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2.

Article Snippet: GAD67 , Boster , Rabbit , 67 , 1:500 , BA0603-2.

Techniques: Injection, Western Blot, Over Expression, Saline, Adjuvant

Journal: Brain Communications

doi: 10.1093/braincomms/fcag138

Figure Lengend Snippet: ErbB4 is the downstream target of GnRH signalling to regulate the E/I balance and pain-related depression-like behaviour induced by CFA injection . ( A ) The localization of GnRHR (green) with ErbB4 (red) in the ACC of mice, bar = 200 μm. ( B ) Effects of Trip treatment on the protein level of p-ErbB4 are demonstrated by western blot and the semiquantitative analysis of p-ErbB4 relative to ErbB4, and the original uncropped blots are shown in . ( C ) Effects of GnRH overexpression on the protein levels of p-ErbB4 are demonstrated by western blot and the semiquantitative analysis of p-ErbB4 relative to ErbB4, and the original uncropped blots are shown in . ( D ) The experimental timeline for Trip and dacomitinib treatment after CFA injection. ( E ) Effects of Trip and dacomitinib treatment on the total movement distance of mice in the OFT. ( F ) Effects of Trip and dacomitinib treatment on the sucrose preference rate of 1% sucrose solution in the SCPT. ( G ) Effects of Trip and dacomitinib treatment on the immobility time within 4 min in the TST. ( H ) Effects of Trip and dacomitinib treatment on the immobility time within 4 min in the FST. ( I ) Effects of Trip and dacomitinib treatment on the protein levels of p-ErbB4, GAD67, VGAT, vGluT1 and vGluT2 are demonstrated by western blot and the semiquantitative analysis of these proteins relative to ErbB4 or β-actin, and the original uncropped blots are shown in . n = 6 mice per group for western blot test and n = 4–5 per group for behaviour tests and any value >2 SD from the group mean was considered an outlier and excluded from the analysis. One-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among Trip or dacomitinib treatment groups. Two-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among Lv-GnRH overexpression groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; ErbB4, Erb-B2 receptor tyrosine kinase 4; p-ErbB4, phosphorylated-Erb-B2 receptor tyrosine kinase 4; Lv, lentivirus; GFP, green fluorescent protein; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; OE, over expression; Trip, triptorelin; Dac, dacomitinib; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2; OFT, open field test; SCPT, sucrose preference test; TST, tail suspension test; FST, forced swimming test.

Article Snippet: GAD67 , Boster , Rabbit , 67 , 1:500 , BA0603-2.

Techniques: Injection, Western Blot, Over Expression, Saline, Adjuvant, Suspension

Journal: Brain Communications

doi: 10.1093/braincomms/fcag138

Figure Lengend Snippet: GnRH activates ErbB4 via the PKC pathway in the ACC of mice after CFA injection . ( A ) Effects of Trip treatment on the protein levels of PKCα and p-MARCKS are demonstrated by western blot and the semiquantitative analysis of PKCα and p-MARCKS relative to β-actin and MARCKS, and the original uncropped blots are shown in . ( B ) The experimental timeline for Trip and bisindolylmaleimide I treatment after CFA injection. ( C ) Effects of Trip and bisindolylmaleimide I treatment on the total movement distance by mice in the OFT. ( D ) Effects of Trip and bisindolylmaleimide I treatment on the sucrose preference rate of 1% sucrose solution in the SCPT. ( E ) Effects of Trip and bisindolylmaleimide I treatment on the immobility time within 4 min in the TST. ( F ) Effects of Trip and bisindolylmaleimide I treatment on the immobility time within 4 min in the FST. ( G ) Effects of Trip and bisindolylmaleimide I treatment on the protein levels of PKCα, p-MARCKS and p-ErbB4 were demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, MARCKS and ErbB4, and the original uncropped blots are shown in . ( H ) Effects of Trip and bisindolylmaleimide I treatment on the protein levels of GAD67, VGAT, vGluT1 and vGluT2 demonstrated by western blot and the semiquantitative analysis of these proteins relative to β-actin, and the original uncropped blots are shown in . n = 6 mice for western blot test and n = 6–9 mice per group for behaviour tests and any value >2 SD from the group mean was considered an outlier and excluded from the analysis. One-way ANOVAs followed by Bonferroni’s post hoc testing for multiple comparisons among the groups. Each data point represents the data of one mouse. * P < 0.05, ** P < 0.01 and *** P < 0.001. Abbreviations: ACC, anterior cingulate cortex; NS, normal saline; CFA, complete Freund’s adjuvant; ErbB4, Erb-B2 receptor tyrosine kinase 4; p-ErbB4, phosphorylated-Erb-B2 receptor tyrosine kinase 4; GnRH, gonadotropin-releasing hormone; GnRHR, gonadotropin-releasing hormone receptor; PKCα, protein kinase C α; MARCKS, myristoylated alanine-rich C kinase substrate; p-MARCKS, phosphorylated-myristoylated alanine-rich C kinase substrate; Trip, triptorelin; Bis I, bisindolylmaleimide I; GAD67, glutamate decarboxylase 67; VGAT, vesicular γ-aminobutyric acid transporter; vGluT1, vesicular glutamate transporter 1; vGluT2, vesicular glutamate transporter 2; OFT, open field test; SCPT, sucrose preference test; TST, tail suspension test; FST, forced swimming test.

Article Snippet: GAD67 , Boster , Rabbit , 67 , 1:500 , BA0603-2.

Techniques: Injection, Western Blot, Saline, Adjuvant, Suspension

Review

Structured Review

Images

1) Product Images from "Gonadotropin-releasing hormone alleviates chronic pain-related depression in male mice by rebalancing the anterior cingulate cortex excitatory-inhibitory processes via the protein kinase C/Erb-B2 receptor tyrosine kinase 4 pathway"

Similar Products

Image Search Results